TAYSHA GENE THERAPIES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.585 USD | +7.71% |
|
+3.43% | +44.92% |
Presentation Operator MessageOperator (Operator)Welcome to the Taysha Gene Therapies Fourth Qu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Companyâs lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
Calendar
2024-05-13
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.4
USD
Average target price
6.833
USD
Spread / Average Target
+184.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.92% | 449M | |
| +27.48% | 48.16B | |
| -0.73% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +10.66% | 25.59B | |
| -22.64% | 18.96B | |
| +8.16% | 12.92B | |
| +29.29% | 12.03B | |
| -1.99% | 11.77B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Transcript : Taysha Gene Therapies, Inc., Q4 2021 Earnings Call, Mar 31, 2022